Effect of Short Course of Glucocorticoid in Patients With Diabetes Mellitus(DM) Type 2

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-03

Study Completion Date

2017-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Participants will receive prednisone 40 mg for 3 days. 75 g oral glucose tolerance test (OGTT), insulin and C-peptide will be measured on day 1 (before prednisone) and day 3 (after prednisone). Also capillary glucose values will be obtained during and after the period of prednisone intake.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Inpatient Diabetes on Corticosteroids

NCT01970241

Diabetes Mellitus

COMPLETED PHASE4

Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects

NCT03139305

Obesity

ACTIVE_NOT_RECRUITING PHASE1

Incretin Physiology Associated With Steroid Hormone Treatment

NCT00713440

Type 2 Diabetes Mellitus Steroids

COMPLETED NA

Effects of Glucagon Administration on Energy Expenditure

NCT02237053

Hyperglucagonemia Obesity

COMPLETED PHASE1

Effect of Glucocorticoid on Exogenous Insulin Antibody Syndrome

NCT04357392

Diabetes Mellitus, Type 2

UNKNOWN EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

On their scheduled day, participants will be instructed to come to the clinic after an overnight fast of a minimum of 8 hours (subjects can drink water). The participants will be asked to refrain from drinking alcohol for a period of 24 hours before the study days and to not perform strenuous exercise for a period of 48 hours before the study days. The participants will be directed to avoid alcohol and strenuous exercise for the duration of the study.

On days 1 and 3 of the study period, participants will be checked into the clinic. A physical examination, including height, weight and waist circumference, and finger-stick glucose will be performed. A 75-g OGTT will be performed with venous samples for measurement of glucose, insulin and C-peptide levels obtained at 0, 30 and 60 minutes starting immediately after the ingestion of the 75 g glucose solution. After samples are collected on day 1, participants will be administered their first dose of steroid, prednisone 40 mg, and be given a packet of two additional doses for the rest of the study period. The investigators may only give 1 additional dose to them and have the participants take the last dose in clinic on day 3 two hours before the OGTT. Subjects will take prednisone 40 mg once daily for three days to be consumed around 8:00am on days 2 and 3. This dose was chosen as a typical high-dose glucocorticoid regimen. On the third day, the participants will again visit the clinic after an overnight fast of a minimum 8 hours and undergo a physical examination and OGTT just as on day 1.

Participants will be instructed to check pre-prandial (before breakfast, lunch and dinner), and bed time (around 10:00 pm) blood glucose (BG) levels and to record all values for a total of five days (three days while on prednisone and for two days after the second study visit). A member of the study staff will call each participant daily around 7:00 pm to obtain BG values. Compliance with the study protocol will be assessed at this time as well. Any subject not compliant with study medications will be excluded from the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Hyperglycemia Steroid-induced

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Two groups. Condition group and Control group, both receiving the investigated medication using the same protocol

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Prednisone in subjects with Diabetes

Group of subjects with diabetes mellitus type 2 receiving prednisone 40 mg po q day for 3 days

Group Type EXPERIMENTAL

Prednisone

Intervention Type DRUG

40 mg po q day of Prednisone for 3 days

Prednisone in control subjects

Group of subjects without diabetes mellitus type 2 receiving prednisone 40 mg po q day for 3 days

Group Type EXPERIMENTAL

Prednisone

Intervention Type DRUG

40 mg po q day of Prednisone for 3 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Prednisone

40 mg po q day of Prednisone for 3 days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Deltasone, Prednicot, Rayos

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males or non-pregnant females between the ages of 18-50 years being followed in the Diabetes Center.
2. Type 2 Diabetes for ≤ 1 year and only on metformin
3. BMI 24.0-35.0 kg/ m2
4. HBA1c ≤ 9.0%

1. Males or non-pregnant females between the ages of 18-50 years in good physical health as determined by medical history, physical examination, and screening blood tests
2. Normoglycemia defined by fasting plasma glucose \< 5.6 mmol/L (or 100 mg/dL) and 2h glucose \<7.8 mmol/L (or 140 mg/dL) after a 75 g OGTT
3. BMI: 22.0 - 28.0 kg/m2

Exclusion Criteria

1. Patients on any other antidiabetes medication.
2. Patients with impaired renal function (estimated Glomerular Filtration Rate (GFR) less than 60 ml/min based on results from Cerner).
3. Patient who have received glucocorticoid therapy within six months of study.
4. Patients who do shift work.
5. Blood glucose level ≥ 250 mg/dl on finger-stick at clinic visit.
6. Signs or symptoms of infection.

Control Group

1. Presence of any disease or use of any medication
2. Patients with a first-degree relative with Type 2 Diabetes
3. Patients who smoke
4. Patients with history of steroid use in previous 6 months.
5. Patients who do shift work
6. Signs or symptoms of infection.
7. Patients with recent changes in weight or physical activity

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes